Valuation: Assertio Holdings

Market Cap 152M 135M 126M 115M 216M 14.6B 218M 1.52B 591M 7.46B 570M 558M 23.95B P/E 2024
-3.79x
P/E 2025 -1.91x
Enterprise Value 129M 114M 107M 97.28M 183M 12.37B 185M 1.29B 501M 6.33B 483M 473M 20.3B EV / Sales 2024
0.19x
EV / Sales 2025 0.3x
Free-Float
99.05%
Yield 2024 *
-
Yield 2025 -
1 day+0.09%
6 months+22.33%
Current year+159.10%
Current year 9.11
Extreme 9.11
23.5
1 year 8.61
Extreme 8.61
23.5
3 years 7.71
Extreme 7.705496
39
5 years 7.71
Extreme 7.705496
120.15
10 years 7.71
Extreme 7.705496
1,569
Director TitleAgeSince
Director/Board Member 26 2026-06-15
Director/Board Member - 2026-06-15
Date Insider Type Main position Quantity % Market Cap. Importance
5/13/26 Don

Chairman

-13,332 0.2069%
5/5/26 Free

Chairman

4,851 0.0753%
5/5/26 Free

Director

4,851 0.0753%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%-.--%+72.26%-38.08% 152M
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
-0.95%-4.05%+20.54%+41.71% 333B
-1.46%-2.89%+10.57%+32.81% 267B
-1.35%-5.43%-6.17%+8.98% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.68%-3.16%+30.69%+48.98% 369.73B
Weighted average by Cap. -0.60%-3.54%+29.07%+70.56%

Financials

2024 2025
Net sales 125M 111M 104M 94.45M 178M 12.01B 180M 1.25B 486M 6.14B 469M 459M 19.71B 119M 105M 98.45M 89.73M 169M 11.41B 171M 1.19B 462M 5.83B 446M 436M 18.72B
Net income -21.58M -19.17M -17.9M -16.31M -30.76M -2.07B -31.05M -217M -83.92M -1.06B -81.03M -79.27M -3.4B -30.38M -26.99M -25.19M -22.96M -43.3M -2.92B -43.7M -305M -118M -1.49B -114M -112M -4.79B
Net Debt -59.79M -53.12M -49.58M -45.19M -85.23M -5.75B -86.02M -600M -233M -2.94B -224M -220M -9.43B -23.15M -20.57M -19.2M -17.5M -33M -2.23B -33.31M -232M -90.03M -1.14B -86.92M -85.04M -3.65B
Logo Assertio Holdings
Assertio Holdings Inc is a United States-based commercial pharmaceutical company. The Company focused on the marketing and distribution of branded prescription medicines across several therapeutic categories. It maintains a portfolio that includes treatments for neurology disorders, inflammatory conditions, pain management, and oncology. Its activities involve acquiring, licensing, and integrating approved pharmaceutical products, followed by commercialization within the healthcare market. Its operating approach centers on identifying products that have established regulatory clearance and advancing their reach through targeted sales, medical education, and market access efforts. It manages product lifecycles through activities such as labeling updates, supply coordination, and engagement with healthcare professionals and payers.
Employees
53
  1. Stock Market
  2. Stocks
  3. ASRT Stock